Phase II study of dasatinib (BMS-354825) in relapsed chronic lymphocytic leukemia.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Mar 2007 New trial record.